Drug Trial Radar · NCT04442737
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Jul 1, 2020
Primary completion
Aug 7, 2023
Study completion Aug 30, 2023
Sponsor
- Lead sponsor
- Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) (Immediate Switch Arm) compared to continuing the current integrase (INI) + tenofovir alafenamide/emtricitabine (TAF/FTC) antiretroviral (ARV) regimen (Delayed Switch Arm) in virologically-suppressed human immunodeficiency virus (HIV)-1 infected participants who have experienced rapid and significant body weight gain.
Conditions
- HIV-1
Interventions
D/C/F/TAF FDCDrug
A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
TAF/FTC FDCDrug
TAF/FTC ARV regimen will be administered once daily.
INI Based RegimenDrug
The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight at Week 24Time frame: Baseline and Week 24
- Percent Change From Baseline in Body Weight at Week 24: Body Mass Index (BMI) >=30 Kilograms Per Square Meter (kg/m^2) SubgroupTime frame: Baseline and Week 24
- Percent Change From Baseline in Body Weight at Week 24: Female and Male SubgroupTime frame: Baseline and Week 24
- Percent Change From Baseline in Body Weight at Week 24: Black/African American and Black/African American- Female SubgroupsTime frame: Baseline and Week 24
- Percent Change From Baseline in Body Weight at Week 24: Non-Black/African American SubgroupTime frame: Baseline and Week 24
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
The Office of Franco Felizarta, MD
Bakersfield, California
AIDS Health Foundation-Westside HCC
Beverly Hills, California
Long Beach Education & Research Consultants
Long Beach, California
Midway Immunology and Research Center
Ft. Pierce, Florida
University of Miami
Miami, Florida
Triple O Research Institute
West Palm Beach, Florida
Atlanta ID Group
Atlanta, Georgia
Medical College of Georgia
Augusta, Georgia
The Corporation of Mercer University
Macon, Georgia
Chatham County Health Department
Savannah, Georgia
The Ruth M. Rothstein CORE Center
Chicago, Illinois
Care South Clinic
Baton Rouge, Louisiana
Kaiser Permanente
Rockville, Maryland
Community Research Initiative
Boston, Massachusetts
Be Well Medical Center, PC
Berkley, Michigan
Henry Ford Health System
Detroit, Michigan
University of Mississippi Medical Center
Jackson, Mississippi
Washington University School Of Medicine
St Louis, Missouri
University of Nebraska
Omaha, Nebraska
Saint Michaels Medical Center - Infectious Disease
Newark, New Jersey
AIDS Healthcare Foundation-Research Center
New York, New York
Mount Sinai Hospital-New York
New York, New York
Montefiore Medical Center
The Bronx, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Philadelphia Fight
Philadelphia, Pennsylvania
Palmetto Health - USC
Columbia, South Carolina
AIDS Arms Incorporated Trinity Health and Wellness Center
Dallas, Texas
North Texas Infectious Diseases Consultants
Dallas, Texas
Texas Centers for Infectious Disease Associates
Fort Worth, Texas
Therapeutic Concepts - Donald R Watkins Foundation
Houston, Texas
DCOL Center for Clinical Research
Longview, Texas
Infectious Disease Associates of Central Virginia
Lynchburg, Virginia
Vivent Health
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.